Microparticle

Global Platinum Powder Market to Attain Revenue of $84.4 Million by 2030, Propelled by Rising Demand Across Diverse Industrial Sectors, States Kings Research

Retrieved on: 
Monday, February 12, 2024
Oxygen, USD, Platinum, Investment, Transport, Growth, Hydrogen, Conference, Microparticle, Perception, Attention, Nanoparticle, Particle size, Research report, Jewellery, Electricity, Role, PGI, Water, Palladium

On the basis of purity, the market is divided into high purity and standard purity.

Key Points: 
  • On the basis of purity, the market is divided into high purity and standard purity.
  • The high purity segment is projected to account for the largest share of the platinum powder market by the end of the forecast period, reaching a valuation of USD 59.17 million by 2030.
  • The demand for high purity platinum powder is anticipated to witness a surge owing to its exceptional suitability for crucial applications, which, in turn, guarantees consistent and trustworthy performance.
  • Purchase This Comprehensive Research Report for Valuable Market Insights: https://www.kingsresearch.com/buy-now/340
    The market for platinum powder is witnessing significant growth due to the increasing use of hydrogen fuel cell technology.

Global Platinum Powder Market to Attain Revenue of $84.4 Million by 2030, Propelled by Rising Demand Across Diverse Industrial Sectors, States Kings Research

Retrieved on: 
Monday, February 12, 2024
Oxygen, USD, Platinum, Investment, Transport, Growth, Hydrogen, Conference, Microparticle, Perception, Attention, Nanoparticle, Particle size, Research report, Jewellery, Electricity, Role, PGI, Water, Palladium

On the basis of purity, the market is divided into high purity and standard purity.

Key Points: 
  • On the basis of purity, the market is divided into high purity and standard purity.
  • The high purity segment is projected to account for the largest share of the platinum powder market by the end of the forecast period, reaching a valuation of USD 59.17 million by 2030.
  • The demand for high purity platinum powder is anticipated to witness a surge owing to its exceptional suitability for crucial applications, which, in turn, guarantees consistent and trustworthy performance.
  • Purchase This Comprehensive Research Report for Valuable Market Insights: https://www.kingsresearch.com/buy-now/340
    The market for platinum powder is witnessing significant growth due to the increasing use of hydrogen fuel cell technology.

First Patient Enrolled in Merit Medical’s MOTION Study

Retrieved on: 
Tuesday, January 16, 2024
Injection, IDE, Osteoarthritis, Patient, Risk, Hypervascularity, Evidence-based medicine, MD, Knee, Incidence, Microparticle, FDA, Pain, Inflammation, Blood, MMSI, GAE, Prevalence, Pharmaceutical industry

Under this designation, Embosphere Microspheres received priority review by the FDA, which allowed for accelerated review and development of the MOTION study protocol.

Key Points: 
  • Under this designation, Embosphere Microspheres received priority review by the FDA, which allowed for accelerated review and development of the MOTION study protocol.
  • In conducting the study, Merit intends to randomize patients 1:1 to receive either GAE using Embosphere Microspheres or intra-articular corticosteroid injections.
  • The study is structured to evaluate primary safety and effectiveness of Embosphere Microspheres at 6 months with continued patient follow up through 24 months.
  • “The commencement of this randomized controlled study is a testament to our commitment to evidence-based medicine and patient-centric care,” said Sandeep Bagla, MD, Co-Global Principal Investigator of the MOTION study.

Rafarma Pharmaceutical news update

Retrieved on: 
Thursday, November 30, 2023
Transfer, SMART, Accounting, Biotechnology, Government, Research, Nuclear medicine, Republic, Microparticle, Legislation, Bank statement, Investment, OTC, GAAP, Audit

Russia, Moscow, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA).

Key Points: 
  • Russia, Moscow, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA).
  • Once the geopolitical climate changes, the company intends to complete the audit of these two assets and add them to the consolidated audited accounts.
  • Meanwhile, the company is working on and acquiring several assets and projects located in Kazakhstan, Israel, El Salvador, Sri Lanka and Hong Kong.
  • The company is currently working with its auditor and will submit standard GAAP audit reports that will include the acquired assets.

Gastroretentive Drug Delivery Systems Outsourcing Market Analysis Report 2023: Increased Focus on Localized Drug Delivery - Global Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 29, 2023
Health, Pharmaceutical, Research, Disorder, GERD, Investment, Tablet, Administration, Microparticle, USD, Tropical ulcer, COVID-19, IBD, Lonza, Nanotechnology, Gastrointestinal tract, Gastroesophageal reflux disease, Inflammatory bowel disease, Fine chemical, Pharmaceutical industry, Capsule

The "Gastroretentive Drug Delivery Systems Outsourcing Market Size, Share & Trends Analysis Report By Dosage Form (Tablets, Liquid, Microspheres, Capsule, Others), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Gastroretentive Drug Delivery Systems Outsourcing Market Size, Share & Trends Analysis Report By Dosage Form (Tablets, Liquid, Microspheres, Capsule, Others), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global gastroretentive drug delivery systems outsourcing market size is expected to reach USD 2.27 billion by 2030.
  • Furthermore, an increased focus on localized drug delivery is expected to boost market growth.
  • Gastroretentive drug delivery systems are indicated for localized drug delivery applications in the gastrointestinal tract.

ABK Biomedical announces that its Eye90 microspheres® device has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA)

Retrieved on: 
Tuesday, December 5, 2023
Microparticle, HCC, Research, Safety, Patient, Hepatocellular carcinoma, Food, IDE, ABK, Diagnosis, FDA, Pharmaceutical industry, NS

HALIFAX, NS, Dec. 5, 2023 /PRNewswire/ - ABK Biomedical, Inc. , an innovative, medical device company dedicated to the research, development, and commercialization of advanced imageable embolic therapies, announces its Eye90 microspheres device has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA).

Key Points: 
  • HALIFAX, NS, Dec. 5, 2023 /PRNewswire/ - ABK Biomedical, Inc. , an innovative, medical device company dedicated to the research, development, and commercialization of advanced imageable embolic therapies, announces its Eye90 microspheres device has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA).
  • This designation is for the proposed Eye90 microspheres indication for the treatment of patients living with unresectable Hepatocellular Carcinoma (HCC).
  • "We are pleased with the FDA's decision to grant Breakthrough Device Designation for Eye90 microspheres Y90 radioembolization device.
  • Dr. Aravind Arepally, Chief Medical Officer of ABK Biomedical, stated, "Eye90 microspheres radioembolization marks a significant breakthrough in the treatment of HCC.

ABK Biomedical Announces First Patient Treated in its Multi-Center Pivotal Study of Eye90 microspheres® in Hepatocellular Carcinoma

Retrieved on: 
Tuesday, October 24, 2023
Radiation therapy, FDA, HCC, Trial of the century, Incidence, Microparticle, NS, Research, Liver cancer, Cancer, Safety, Patient, ABK, Medical imaging, MD

The Eye90 microspheres radioembolization procedure was performed by Eric A. Wang, MD, FSIR, with Charlotte Radiology in Charlotte NC.

Key Points: 
  • The Eye90 microspheres radioembolization procedure was performed by Eric A. Wang, MD, FSIR, with Charlotte Radiology in Charlotte NC.
  • The Route90 pivotal clinical study is designed to evaluate the safety and efficacy of Eye90 microspheres in patients living with unresectable HCC.
  • The study will evaluate HCC tumors' response rates and duration of response from Eye90 microspheres treatment as co-primary endpoints.
  • "The Route90 pivotal study will not only confirm the effectiveness of Eye90 treatment but will also establish the importance of 3D radiation dosimetry in advancing therapy and patient outcomes.

VESSELON TOWN HALL EVENT PROVIDES A GLIMPSE INTO THE FUTURE OF INTRAVENOUS DRUG DEVELOPMENT

Retrieved on: 
Thursday, September 7, 2023
Liposome, Tissue, Drug development, Q&A, Neoplasm, CMC, IP, Doctor of Philosophy, Hospital, Acquisition, Patent, Keltner, Patient, Risk, Biophysics, Cavitation, FDA, Microparticle, Tumor microenvironment, News, Pharmaceutical industry, Medical imaging

GREENWICH, Conn., Sept. 7, 2023 /PRNewswire/ -- In a digital town hall discussion held with industry analysts, Vesselon CEO and Co-founder Clay Larsen delivered a glimpse into the future of drug development that could revolutionize the pharmaceutical industry. The event, moderated by Endpoints News, showcased how Vesselon's drug platform can extend patents and rapidly create an endless stream of proprietary drugs. The company's bold strategy could yield multiple billion-dollar drug co-formulations by 2030 and redefine the boundaries of drug patents. Sharing the virtual stage with Larsen were EPISTAT CEO Llew Keltner MD, PhD and iECURE Inc. CEO Joe Truitt,

Key Points: 
  • GREENWICH, Conn., Sept. 7, 2023 /PRNewswire/ -- In a digital town hall discussion held with industry analysts, Vesselon CEO and Co-founder Clay Larsen delivered a glimpse into the future of drug development that could revolutionize the pharmaceutical industry.
  • The event, moderated by Endpoints News, showcased how Vesselon's drug platform can extend patents and rapidly create an endless stream of proprietary drugs.
  • The company's bold strategy could yield multiple billion-dollar drug co-formulations by 2030 and redefine the boundaries of drug patents.
  • For a comprehensive look at Vesselon's town hall event, including additional insights from industry experts and audience Q&A, visit www.Vesselon.com/townhall .

Vesselon Introduces the First On-site Co-formulation Platform that Dramatically Improves How Cells Receive and Act on Drugs

Retrieved on: 
Monday, August 28, 2023
Liposome, Tissue, Drug, CMC, Permeability (electromagnetism), Endocytosis, Research, Cell, PGP, Dicarboxylic acid, Patent, NCE, Cell death, Apoptosis, Neoplasm, FDA, Virus, Microparticle, Safety, Fine chemical, Pharmaceutical industry, Medical device, Vaccine

GREENWICH, Conn., Aug. 28, 2023 /PRNewswire/ -- Vesselon Inc. introduced the first on-site co-formulation platform that can enhance cellular uptake and response to therapy, without altering the active drug in any way. Compared to traditional administration methods, Vesselon drugs penetrate targeted cells more effectively and improve a drug's bioavailability by multiple fold.

Key Points: 
  • Compared to traditional administration methods, Vesselon drugs penetrate targeted cells more effectively and improve a drug's bioavailability by multiple fold.
  • Without changing pharmaceutical manufacturing, CMC, or distribution practices, the platform can protect and differentiate an endless stream of blockbuster drugs.
  • "We encapsulate many different classes of drugs, from small molecules, monoclonal antibodies, nucleic acids to viruses," said Clay Larsen, CEO of Vesselon.
  • "I think the best way to think about our approach is that it changes the ability of tissues to receive and act on the drug.

Medical Aesthetics Returning to the True of Medicine - The 5th Anniversary Celebration of SHANGHAI MOYOM BIOTECH (APHRANEL)

Retrieved on: 
Friday, August 25, 2023
Social responsibility, GMP, CAPA, Chinese Academy of Medical Sciences COVID-19 vaccine, Interview, Education, Medicine, Iran National Science Foundation, Speech, University of the Chinese Academy of Sciences, Research, Government, Thought, Philosophy, Beauty, Trust, Patient, Love, Diagnosis, Qi, Microparticle, Safety, Reiko True, Dentistry, Typesetting, Management, Fine chemical

Invited representatives of the medical aesthetics industry held a wonderful discussion and joint oath from the perspective of "Practitioners of returning medical aesthetics to the true of medicine".

Key Points: 
  • Invited representatives of the medical aesthetics industry held a wonderful discussion and joint oath from the perspective of "Practitioners of returning medical aesthetics to the true of medicine".
  • Different from other anniversary celebrations, Shanghai MOYOM's 5th anniversary celebration on August 18, 2023 was more like a collision of ideas and a call of value return in the medical aesthetics industry.
  • Shanghai MOYOM's 5th Anniversary Celebration, it is a big gathering of people in the medical aesthetics industry and a big collision of ideas.
  • Shanghai MOYOM Bio is not only an enterprise, but also the practitioner and guardian of the clean environment of the medical aesthetics industry.